NCT05440344View on ClinicalTrials.gov

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Hepatic InsufficiencyHealthy
Interventions
DRUG

Imlunestrant

Administered orally.

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

78215

American Research Corporation at Texas Liver Institute, San Antonio

92377

Inland Empire Liver Foundation, Rialto

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY